At a glance
ClinicalIndex Comparison RecordN/AUnknown· 100 target
Drug / intervention
Palbociclibdrug
Likely dose
Palbociclib 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Multicenter Study for the Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
In Brief
An observational study evaluating Palbociclib for Breast Cancer. Targeting 100 participants across 1 site.
Detailed Summary
This is a multi-center, observational study designed to explore the regulatory mechanism of palbociclib correlative pathways in therapeutic process of breast cancer, employing next generation sequencing (NGS) on DNA and RNA. This study also monitor the clonal evolution of genes by tracing the ctDNA.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
CollaboratorsOrigiMed
Timeline
N/AUnknownOverdue
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedFeb 2020
Primary CompletionJun 2020
Study CompletionApr 2022
TodayJul 2026
First PostedFeb 28, 2020
Enrollment StartFeb 14, 2019
Primary CompletionJun 1, 2020
Study CompletionApr 1, 2022
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 6.3 years ago
Interventions
Palbociclibdrug
Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)